These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. The role of chemotherapy for advanced oro and hypopharyngeal cancer. Kohno N Auris Nasus Larynx; 2004 Jun; 31(2):113-8. PubMed ID: 15121218 [TBL] [Abstract][Full Text] [Related]
68. Combined modality therapy for laryngeal and hypopharyngeal cancer. Sannazzari GL; Gabriele P; Redda MG; Verna R Rays; 1997; 22(3):360-71. PubMed ID: 9446940 [TBL] [Abstract][Full Text] [Related]
69. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Strome SE; Sausville EA; Mann D Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078 [TBL] [Abstract][Full Text] [Related]
74. Options for preserving the larynx in patients with advanced laryngeal and hypopharyngeal cancer. Wolf GT Ear Nose Throat J; 2001 Dec; 80(12):897-901. PubMed ID: 11775526 [TBL] [Abstract][Full Text] [Related]
75. Monoclonal antibodies for therapy of human malignant tumours. Bergh JC Eur J Surg Suppl; 1991 May; (561):59-64. PubMed ID: 1720051 [No Abstract] [Full Text] [Related]
76. Squamous cell carcinoma of the oropharynx and hypopharynx. Lin DT; Cohen SM; Coppit GL; Burkey BB Otolaryngol Clin North Am; 2005 Feb; 38(1):59-74, viii. PubMed ID: 15649499 [TBL] [Abstract][Full Text] [Related]